| 1 |
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs
Peter L. Turecek, Mary J. Bossard, Freddy Schoetens et al. · Journal of Pharmaceutical Sciences
Open access |
29 Jan 2016 |
734 |
| 2 |
A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1
Gabriela M. Stiegler, Renate Kunert, Martin Purtscher et al. · AIDS Research and Human Retroviruses
|
10 Dec 2001 |
521 |
| 3 |
Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, double-blinded, placebo-controlled, dose-finding study
Ester D. de Kleijn, Ronald de Groot, C. Erik Hack et al. · Critical Care Medicine
|
Jun 2003 |
440 |
| 4 |
The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement Therapy
Helen M Chapel, Gavin Spickett, Diddi Ericson et al. · Journal of Clinical Immunology
|
Mar 2000 |
328 |
| 5 |
Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
P. W. COLLINS, Victor S. Blanchette, Kathelijn Fischer et al. · Journal of Thrombosis and Haemostasis
Open access |
21 Dec 2008 |
324 |
| 6 |
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases
Michael Rieger · Blood
|
12 May 2005 |
316 |
| 7 |
Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II
James Alan Tumlin, Raghavan Murugan, Adam M. Deane et al. · Critical Care Medicine
Open access |
6 Mar 2018 |
300 |
| 8 |
Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity
Silvia Ferrari et al. · Blood
|
12 Dec 2006 |
298 |
| 9 |
Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines
Perry Barrett, Wolfgang Mundt, Otfried Kistner et al. · Expert Review of Vaccines
|
27 Apr 2009 |
286 |
| 10 |
A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture
Hartmut J. Ehrlich, Markus Müller, Helen May‐Lin Oh et al. · New England Journal of Medicine
Open access |
11 Jun 2008 |
276 |
| 11 |
von Willebrand factor–cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke
Bing–Qiao Zhao, Anil Kumar Chauhan, Matthias Canault et al. · Blood
Open access |
17 Aug 2009 |
264 |
| 12 |
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension
Diana Bonderman, Peter L. Turecek, Johannes Jakowitsch et al. · Thrombosis and Haemostasis
|
2003 |
259 |
| 13 |
Nonneutralizing IgM and IgG antibodies to von Willebrand factor–cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura
Friedrich Scheiflinger, Paul Knöbl, Bettina Trattner et al. · Blood
|
15 Jul 2003 |
235 |
| 14 |
Binding of disease-associated prion protein to plasminogen
Michael Bernhard Fischer, Christiane Roeckl, Petra Parizek et al. · Nature
|
Nov 2000 |
226 |
| 15 |
Development of a mammalian cell (Vero) derived candidate influenza virus vaccine
Otfried Kistner · Vaccine
|
May 1998 |
223 |
| 16 |
Systemic antithrombotic effects of ADAMTS13
Anil Kumar Chauhan, David G. Motto, Colin B. Lamb et al. · The Journal of Experimental Medicine
Open access |
13 Mar 2006 |
222 |
| 17 |
Delineation of Borrelia burgdorferi sensu lato species by multilocus sequence analysis and confirmation of the delineation of Borrelia spielmanii sp. nov.
D. Richter, Danièle Postic, Natacha Sertour et al. · INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY
|
Apr 2006 |
222 |
| 18 |
Activated protein C inhibits lipopolysaccharide‐induced nuclear translocation of nuclear factor κB (NF‐κB) and tumour necrosis factor α (TNF‐α) production in the THP‐1 monocytic cell line
B. Douglas White, Marcus Schmidt, Cathriona Murphy et al. · British Journal of Haematology
|
Jul 2000 |
221 |
| 19 |
Safety of factor VIII inhibitor bypass activity (FEIBA®): 10‐year compilation of thrombotic adverse events
Hartmut J. Ehrlich, M. J. HENZL, Edward D. Gomperts · Haemophilia
|
Mar 2002 |
220 |
| 20 |
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura
Christoph Klaus, Barbara Plaimauer, Jan–Dirk Studt et al. · Blood
|
24 Feb 2004 |
219 |
| 21 |
ADAMTS13: a new link between thrombosis and inflammation
Anil Kumar Chauhan, Janka Kisucka, Alexander G. Brill et al. · The Journal of Experimental Medicine
Open access |
11 Aug 2008 |
218 |
| 22 |
Viral contamination in biologic manufacture and implications for emerging therapies
Paul W. Barone et al. · Nature Biotechnology
Open access |
27 Apr 2020 |
215 |
| 23 |
Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
Sven Erik Björkman, Myungshin Oh, Gerald E. Spotts et al. · Blood
Open access |
Nov 2011 |
208 |
| 24 |
IgG subclass distribution of anti‐ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura
Silvia Ferrari, Geert C. Mudde, Michael Rieger et al. · Journal of Thrombosis and Haemostasis
Open access |
11 Aug 2009 |
201 |
| 25 |
Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients
Shawn F. J. Whelan, Christoph J. Hofbauer, Frank Michael Horling et al. · Blood
|
14 Dec 2012 |
186 |
| 26 |
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens
Peter W. Collins, Sven Erik Björkman, Kathelijn Fischer et al. · Journal of Thrombosis and Haemostasis
Open access |
23 Nov 2009 |
186 |
| 27 |
New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development
Karin Kurnik, Christoph Bidlingmaier, Werner Engl et al. · Haemophilia
|
30 Oct 2009 |
178 |
| 28 |
WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer
Peter Wend, Stephanie Runke, Korinna Wend et al. · EMBO Molecular Medicine
Open access |
11 Jan 2013 |
176 |
| 29 |
Efficacy and safety of OBI ‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A
Rebecca Kruse‐Jarres, Jean St‐Louis, A. Greist et al. · Haemophilia
Open access |
27 Jan 2015 |
175 |
| 30 |
FEIBA®: mode of action
Peter L. Turecek, Katalin Váradi, Herbert Gritsch et al. · Haemophilia
|
Sep 2004 |
170 |
| 31 |
Low ADAMTS13 activity is associated with an increased risk of ischemic stroke
Michelle Sonneveld, Moniek P.M. de Maat, Marileen L.P. Portegies et al. · Blood
|
28 Oct 2015 |
169 |
| 32 |
A survey of adherence to haemophilia therapy in six European countries: results and recommendations
Philippe de Moerloose, W. Urbancik, H. Marijke van den Berg et al. · Haemophilia
Open access |
5 Aug 2008 |
168 |
| 33 |
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?
Christian Lubich, Peter Allacher, Maurus de la Rosa et al. · Pharmaceutical Research
|
7 Jun 2016 |
165 |
| 34 |
Fibrin–Polyurethane Composites for Articular Cartilage Tissue Engineering: A Preliminary Analysis
Cynthia R. Lee, Sibylle Grad, Katarzyna Górna et al. · Tissue Engineering
|
Sep 2005 |
161 |
| 35 |
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience
Y. Benhamou et al. · Haematologica
Open access |
11 May 2012 |
159 |
| 36 |
Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin
Jan–Dirk Studt, Johanna A. Kremer Hovinga, Gerhard Antoine et al. · Blood
Open access |
14 Sep 2004 |
159 |
| 37 |
Comprehensive glyco‐proteomic analysis of human α1‐antitrypsin and its charge isoforms
Daniel Kolarich, Alfred Weber, Peter L. Turecek et al. · PROTEOMICS
|
18 Apr 2006 |
155 |
| 38 |
Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays
Lisa Weidner, Simon Gänsdorfer, Stephan Unterweger et al. · Journal of Clinical Virology
Open access |
6 Jul 2020 |
153 |
| 39 |
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy
Michèle Cavo, Elena Zamagni, Claudia Cellini et al. · Blood
Open access |
28 Aug 2002 |
152 |
| 40 |
Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency
Richard L. Wasserman, Isaac Melamed, Mark R. Stein et al. · Journal of Allergy and Clinical Immunology
Open access |
28 Jul 2012 |
151 |
| 41 |
ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense
Thomas P. C. Monath, Joseph R. Caldwell, Wolfgang Mundt et al. · International Journal of Infectious Diseases
Open access |
Oct 2004 |
148 |
| 42 |
Emerging trends in plasma‐free manufacturing of recombinant protein therapeutics expressed in mammalian cells
Leopold Grillberger, Thomas R. Kreil, Sonia Ben Nasr et al. · Biotechnology Journal
Open access |
Feb 2009 |
143 |
| 43 |
Monitoring the bioavailability of FEIBA with a thrombin generation assay
Katalin Váradi, Claude Négrier, Erik E. Berntorp et al. · Journal of Thrombosis and Haemostasis
Open access |
Nov 2003 |
142 |
| 44 |
Comparison of regenerated and non-regenerated oxidized cellulose hemostatic agents
Kevin M. Lewis, Daniel Spazierer, Manfred Urban et al. · European surgery. Supplement/European surgery
Open access |
3 Jul 2013 |
140 |
| 45 |
Taking immunogenicity assessment of therapeutic proteins to the next level
Isabel Büttel et al. · Biologicals
|
25 Feb 2011 |
140 |
| 46 |
Complement Factor H Mutation in Familial Thrombotic Thrombocytopenic Purpura with ADAMTS13 Deficiency and Renal Involvement
Marina Noris, Sara Bucchioni, Miriam Galbusera et al. · Journal of the American Society of Nephrology
|
30 Mar 2005 |
138 |
| 47 |
Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
Jan Astermark, Carmen Altisent, Angelika Bátorová et al. · Haemophilia
Open access |
14 Apr 2010 |
138 |
| 48 |
Recombinant ADAMTS13 normalizes von Willebrand factor‐cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies
Barbara Plaimauer, Johanna A. Kremer Hovinga, Claudia Juno et al. · Journal of Thrombosis and Haemostasis
Open access |
5 Feb 2011 |
130 |
| 49 |
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial
Pier Mannuccio Mannucci, Christine L. Kempton, Carolyn M. Millar et al. · Blood
Open access |
18 Jun 2013 |
129 |
| 50 |
Improvement of bioprocess monitoring: development of novel concepts
Franz Clementschitsch, Karl Bayer · Microbial Cell Factories
Open access |
22 May 2006 |
129 |